Redwood Investment Management LLC Sells 5,967 Shares of Merck & Co., Inc. $MRK

Redwood Investment Management LLC trimmed its position in shares of Merck & Co., Inc. (NYSE:MRK) by 54.9% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,896 shares of the company’s stock after selling 5,967 shares during the quarter. Redwood Investment Management LLC’s holdings in Merck & Co., Inc. were worth $589,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of MRK. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at $25,000. Abound Financial LLC bought a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $26,000. Prosperity Bancshares Inc bought a new stake in shares of Merck & Co., Inc. during the fourth quarter worth about $26,000. High Note Wealth LLC raised its holdings in shares of Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock worth $31,000 after acquiring an additional 109 shares during the last quarter. Finally, IFC & Insurance Marketing Inc. bought a new position in Merck & Co., Inc. in the 4th quarter valued at about $31,000. 76.07% of the stock is currently owned by institutional investors.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck reported second-quarter revenue of $16.61 billion, above the $16.37 billion consensus estimate and up 5.1% year over year. Adjusted loss per share of $0.13 was also better than the expected $0.26 loss. Merck posts better-than-expected second-quarter results on Keytruda strength
• Positive Sentiment: Keytruda remained the primary growth engine, while the newer injectable version of the cancer treatment exceeded Wall Street expectations by more than $200 million. Strength in oncology and other newer products helped support the improved sales outlook. The Merck Product That Absolutely Demolished Wall Street’s Forecasts
• Positive Sentiment: Merck raised and narrowed its full-year 2026 revenue forecast to $66.3 billion-$67.3 billion, broadly consistent with the $66.7 billion analyst consensus. Management also highlighted regulatory, clinical and pipeline milestones that could support longer-term growth. MRK Q2 Earnings and Sales Beat Estimates, 2026 Sales View Raised
• Negative Sentiment: Merck cut its 2026 EPS guidance to $2.66-$2.76, well below the $3.42 consensus estimate, because of charges associated with the acquisition of Terns Pharmaceuticals. The resulting earnings pressure offsets part of the benefit from the stronger sales outlook. Merck hikes revenue outlook but cuts profit guidance due to deal charges

Merck & Co., Inc. Stock Up 0.4%

Merck & Co., Inc. stock opened at $128.28 on Wednesday. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $135.05. The stock has a market cap of $316.83 billion, a PE ratio of 36.14, a price-to-earnings-growth ratio of 5.07 and a beta of 0.19. The firm’s 50-day simple moving average is $123.45 and its 200 day simple moving average is $118.78. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a net margin of 13.59% and a return on equity of 27.55%. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. During the same quarter last year, the business posted $2.13 EPS. The company’s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Research analysts predict that Merck & Co., Inc. will post 2.74 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be given a dividend of $0.85 per share. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.7%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 95.77%.

Analysts Set New Price Targets

A number of research firms have issued reports on MRK. CICC Research initiated coverage on Merck & Co., Inc. in a research note on Wednesday, June 24th. They set an “outperform” rating and a $138.00 price target for the company. Scotiabank increased their price objective on Merck & Co., Inc. from $136.00 to $155.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, June 30th. Bank of America raised their target price on Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a report on Tuesday, June 30th. Guggenheim lifted their target price on Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, July 13th. Finally, Morgan Stanley lifted their target price on Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Thirteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $134.50.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.